ArticleMolecular cancer therapeutics2022

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.

Niranjan Awasthi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.